# Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

> **NCT04603365** · PHASE2 · WITHDRAWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Clear Cell Papillary Renal Neoplasm
- Collecting Duct Carcinoma
- Hereditary Leiomyomatosis and Renal Cell Carcinoma
- Hereditary Papillary Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Metastatic Unclassified Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma
- Stage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8
- Stage IV Renal Cell Cancer AJCC v8
- Tubulocystic Renal Cell Carcinoma
- Unresectable Renal Cell Carcinoma

## Interventions

- **DRUG:** Pamiparib
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT04603365
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-18
- **Primary completion:** 2023-05-07
- **Final completion:** 2023-05-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** enrollment
- **Last updated:** 2023-05-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04603365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04603365, "Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04603365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*